Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, September 17, 2021
[ Fri, Sep 17th 2021
] - WOPRAI
[ Fri, Sep 17th 2021
] - WOPRAI
[ Fri, Sep 17th 2021
] - WOPRAI
[ Fri, Sep 17th 2021
] - WOPRAI
[ Fri, Sep 17th 2021
] - WOPRAI
[ Fri, Sep 17th 2021
] - WOPRAI
Thu, September 16, 2021
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
[ Thu, Sep 16th 2021
] - WOPRAI
Vikram Purohit Maintained (TBPH) at Sell with Decreased Target to $10 on, Sep 16th, 2021
Vikram Purohit of Morgan Stanley, Maintained "Theravance Biopharma, Inc." (TBPH) at Sell with Decreased Target from $14 to $10 on, Sep 16th, 2021.
Vikram has made no other calls on TBPH in the last 4 months.
There are 2 other peers that have a rating on TBPH. Out of the 2 peers that are also analyzing TBPH, 1 agrees with Vikram's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Marc Frahm of "Cowen & Co." Downgraded from Buy to Hold and Decreased Target to $14 on, Tuesday, August 24th, 2021
This is the rating of the analyst that currently disagrees with Vikram
- Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $18 on, Tuesday, August 24th, 2021
